CD38 and Miyoshi myopathy: In vivo studies performed on a xenograft mouse model demonstrated that the anti-CD38 antibody coated nanoparticles were able to significantly reduce tumor size by four-fold as compared with non-coated nanoparticles, after 12 days drug administration, which indicated that the anti-CD38 antibody on nanoparticles loaded with STAT3 inhibitors can further improve their therapeutic effects against MM.